PharmaCyte Biotech (PMCB) Stock Slumps 70% YTD: Will it Rebound?

September 14, 2021

PharmaCyte Biotech (NASDAQ:PMCB), a company that produces cellular therapies for cancer and diabetes patients, is moving fast and thus a potential buy for the investors. Recently in July the company has announced of enacting a 1-for-1,500 reverse stock split for its common stock which gained effectiveness on the OTCQB Exchange at the opening of the market on July 12. This resulted in the decline the number of outstanding common stock…

Read More >>

PharmaCyte Biotech (OTCMKTS:PMCB) Stock Extends Rally: Up 55% in a Week

June 24, 2021

In recent times, the PharmaCyte Biotech Inc (OTCMKTS:PMCB) stock has emerged as a notable gainer in the biotech space and the strong move has continued this morning. This morning the stock has carried on its momentum and soared by 13% to takes its gains for the past week to as much as 55%. Earlier today, the stock has come on to the radars of investors after it announced the steps…

Read More >>